References
- Nazer LH, Rihani S, Hawari FI, et al. High-dose colistin for microbiologically documented serious respiratory infections associated with carbapenem-resistance Acinetobacter baumanii in critically ill cancer patients: a retrospective cohort study. Infect Dis (London). 2015;47:755–760.
- Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284–3294.
- Imberti R, Cusato M, Villiani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest. 2010;138:1333–1339.
- Falagas ME, Fragoulis KN, Kasiakou SK, et al. Nephrotoxicity of intravenous colistin. Int J Antimicrob Agents. 2005;26:505–507.
- Lee Y, Wi YM, Kwon YJ, et al. Association between colistin dose and development of nephrotoxicity. Crit Care Med. 2015;43:1187–1193.
- Trifi A, Abdellatif S, Daly F, et al. Efficacy and toxicity of high-dose colistin in multidrug-resistant gram-negative bacilli infections: a comparative study of a matched series. Chemotherapy. 2016;61:190–196.
- Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54:1720–1726.
- Phe K, Lee Y, McDaneld PM, et al. Comparison of nephrotoxicity rates associated with colistimethate versus polymyxin B therapy: in vitro assessment and a multicenter cohort study. Antimicrob Agents Chemother. 2014;58:2740–2746.
- Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: is there Any difference between colistimethate and polymyxin B? Antimicrob Agents Chemother. 2017;61:1–10.